Rituximab (MabThera(R)) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation
Knight C, Hind D, Brewer N, Abbott V
Record ID 32004000763
English
Authors' objectives:
A systematic review of the literature was commissioned to determine the clinical and cost-effectiveness of adding rituximab to cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) for adult patients (>=18 years old) with diffuse large B-cell lymphoma (DLBCL). The primary outcome was survival free of progression, relapse or death. Secondary outcomes were overall survival, response rates and toxic effects.
Authors' recommendations:
In the systematic review of effectiveness, one RCT was identified. In the short term, the addition of rituximab to the CHOP regimen significantly increased the likelihood of a complete response, without a significant rise in the risk of a serious adverse event, in people aged >=60 years with stage II-IV DLBCL. Over a 2-year follow-up period, the intervention significantly prolonged survival without progression or relapse (the primary outcome), and significantly prolonged overall survival in this population. There is no direct evidence for the clinical effectiveness of adding rituximab to CHOP in the treatment of DLBCL in those aged 1859 years, although data from phase I and II trials confirm its safety and efficacy in a preclinical setting. Arguments are presented that clinical effectiveness can be derived for a younger population on the grounds that disease biology is consistent by age and prognosis is inversely correlated with age.
Authors' methods:
systematic review, Economic evaluation
Details
Project Status:
Completed
URL for project:
http://www.hta.ac.uk/1344
Year Published:
2004
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Antineoplastic Agents
- Costs and Cost Analysis
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Non-Hodgkin
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
Copyright:
2009 Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.